Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
Author:
Open Access
- 15 July 2022
- journal article
- editorial
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 16 (4) , 497-498
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort StudyClinical Gastroenterology and Hepatology, 2021
- Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the DiseaseClinical Gastroenterology and Hepatology, 2021
- KASL clinical practice guidelines: Management of nonalcoholic fatty liver diseaseClinical and Molecular Hepatology, 2021
- Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver DiseaseGut and Liver, 2021
- MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver DiseaseGastroenterology, 2020
- Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adultsBMJ, 2019
- The economic and clinical burden of nonalcoholic fatty liver disease in the United States and EuropeHepatology, 2016
- Nonalcoholic Fatty Liver DiseaseSeminars in Liver Disease, 2015
- The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort StudyGastroenterology, 2005
- Nonalcoholic fatty liver disease.1986